U.S. markets closed

Catabasis Pharmaceuticals, Inc. (CATB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.7300-0.0100 (-0.36%)
At close: 4:00PM EST

Catabasis Pharmaceuticals, Inc.

100 High Street
28th Floor
Boston, MA 02110
United States
617 349 1971
http://www.catabasis.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees27

Key Executives

NameTitlePayExercisedYear Born
Ms. Jill C. MilneCo-Founder, CEO, Pres & Director734.54kN/A1968
Dr. Andrew J. NicholsChief Scientific Officer512.64kN/A1961
Dr. Joanne M. DonovanChief Medical Officer & Sr. VP of Clinical Devel.594.41kN/A1957
Mr. Noah Clauser CPAChief Financial OfficerN/AN/A1973
Mr. Benjamin S. Harshbarger J.D.Sr. VP & Gen. CounselN/AN/A1969
Mr. Joseph JohnstonSr. VP of Regulatory AffairsN/AN/AN/A
Mr. Andrew A. KomjathyChief Commercial OfficerN/AN/A1963
Ms. Andrea L. MatthewsVP of Corp. AffairsN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. Its lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). The company is also developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a preclinical research collaboration with the Jain Foundation to study edasalonexent in dysferlinopathy; and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in drug-sensitive and drug-resistant tuberculosis. The company was founded in 2008 and is based in Boston, Massachusetts.

Corporate Governance

Catabasis Pharmaceuticals, Inc.’s ISS Governance QualityScore as of January 22, 2021 is 10. The pillar scores are Audit: 1; Board: 10; Shareholder Rights: 10; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.